New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 150mg;  ;   - film coated tablet - 150 mg - active: oxcarbazepine 150mg     excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide black iron oxide red iron oxide yellow macrogol 4000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 300mg;  ;   - film coated tablet - 300 mg - active: oxcarbazepine 300mg     excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide yellow macrogol 8000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 600mg;  ;   - film coated tablet - 600 mg - active: oxcarbazepine 600mg     excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide black iron oxide red macrogol 4000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium iodide(123i) -

Canada - English - Health Canada

ge healthcare canada inc - iobenguane 123 i - solution - 74mbq - iobenguane 123 i 74mbq - roentgenography

Singapore - English - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - tetrakis (2-methoxyisobutyl isonitrile) copper (i) tetrafluoroborate - injection, powder, for solution - 1.0 mg - tetrakis (2-methoxyisobutyl isonitrile) copper (i) tetrafluoroborate 1.0 mg

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levonorgestrel - tablets - levonorgestrel 1.5 mg - levonorgestrel - levonorgestrel - emergency contraseptive.

European Union - English - EMA (European Medicines Agency)

cis bio international - ioflupane (123l) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. striascan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. striascan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.